Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023
SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments...
Pharmaceutical
Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors
Experienced Life Science Operating Leader Joins Board as Company Enters New PhaseSOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE)...
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
IBA is looking for 100 new collaborators in Belgium by June 2023
Louvain-la-Neuve, Belgium, 14 March 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology wants...
Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
Professor Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for Studies of Addiction at the...
Roche Annual General Meeting 2023
All proposals of the Board of Directors approvedSeverin Schwan elected as new Chairman of the Board of Directors; all other...
Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools...
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
Dr. Camille Bedrosian to continue employment as strategic development advisor with the company Eric Crombez, M.D. Eric Crombez, M.D.NOVATO, Calif.,...
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on...
Custom Research Presented at AMIA Informatics Summit Reveals Promising Findings for Healthcare Innovation
SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and...
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results...
World Orphan Drug Alliance Expands to China, Israel, and Greece, Cyprus, and Malta
Greater China region, Israel, and Greece, Cyprus and Malta are now also covered by the alliance. With the addition of...
Culture Biosciences Focuses Technology and Service Platform on Biologics
Intelligent upstream bioprocess development for therapeutics using an integrated platform of cloud-based software, single-use bioreactors, simulation tools, and process development...
EMulate Therapeutics Announces the Addition of Donna Morgan Murray, Ph.D., to its Board of Directors
BELLEVUE, Wash., March 14, 2023 (GLOBE NEWSWIRE) -- EMulate Therapeutics, Inc. (“EMulate” or the “Company”) a clinical-stage company, developing digital...
LSL Group Closes a Complementary and Final Private Placement of $145,000.10 to Its Reverse Takeover
BOUCHERVILLE, Quebec, March 14, 2023 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV : LSL) – LSL Pharma Group Inc. (the...
H1 Launches Advanced Diversity Insights and Clinical Trial Performance Insights
First to offer diversity insights, healthcare data leader H1 expands its offering with two new capabilities focused on supporting diversity...
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2022 Financial Results on March 16, 2023
FREDERICK, Md., March 13, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying,...
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to...
Windtree Regains Compliance with Nasdaq
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...